CDXC - ChromaDex Corporation Quarterly EPS earnings growth

Brandmark of ChromaDex Corp. (CDXC)

The quarterly EPS growth rate demonstrates the impact of ChromaDex Corporation (CDXC) R&D developments in cellular aging and Niagen, with the current level sitting around 5763.70. Leadership in the rejuvenation segment is based on the proven efficacy of its products, while ownership of exclusive patents for the nicotinamide riboside molecule creates a robust defensive barrier against competition.

ChromaDex (CDXC) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 03/19/2025

Analytical breakdowns for ChromaDex Corporation

- market value and analyst target forecast:
Basic company analysis:ChromaDex Corp - CDXC
Manufactured product of chromadex.com

To build a high-quality portfolio, I track net income per share dynamics, utilizing a calculation model that captures daily changes in quarterly EPS growth to identify early signs of factor alpha. Given that ChromaDex Corporation (CDXC) is fully focused on the US domestic market without external risks, the upward trend of the quarterly EPS growth index confirms the business's internal efficiency and the asset's fundamental stability.